Subclinical acromegaly: to treat or not to treat?


Journal

Endocrine journal
ISSN: 1348-4540
Titre abrégé: Endocr J
Pays: Japan
ID NLM: 9313485

Informations de publication

Date de publication:
28 Nov 2022
Historique:
pubmed: 23 6 2022
medline: 30 11 2022
entrez: 22 6 2022
Statut: ppublish

Résumé

Patients with acromegaly usually present with the classical signs of acromegaly, whereas patients without the specific signs or symptoms are rarely diagnosed. This unique entity can be named "subclinical acromegaly". This was a retrospective study. Our study group consisted of 6 patients (4 females) with incidentally diagnosed acromegaly, most following head MRI for unrelated reasons and without the specific signs of acromegaly. Mean age at diagnosis was 48.8 ± 19.2 years. Baseline IGF-1 ranged between 1.3-2.0 × upper limit of normal (ULN). MRI depicted a pituitary microadenoma in 5 patients, and one patient presented with a 12 mm intra-sellar macroadenoma. Mean calculated SAGIT clinical score was 4.8. Three patients underwent trans-sphenoidal resection; two achieved hormonal remission and one improved but did not normalize IGF-1 following surgery. Four patients (including one following surgery) were given somatostatin analogs, and three normalized IGF-1. Several patients improved clinically following treatment, reporting improvement in snoring, hypertension, or weight loss, and pituitary adenoma decreased in size in 2 patients that responded to medical treatment. We report a series of 6 patients with very mild and subclinical acromegaly. It is uncertain whether all such patients will gain clinical benefit from treatment, but most experienced clinical improvement due to treatment.

Identifiants

pubmed: 35732439
doi: 10.1507/endocrj.EJ22-0066
doi:

Substances chimiques

Human Growth Hormone 12629-01-5
Insulin-Like Growth Factor I 67763-96-6
Somatostatin 51110-01-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1323-1328

Auteurs

Ilan Shimon (I)

Institute of Endocrinology, Rabin Medical Center - Beilinson Hospital, Petach Tikva 4941492, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Zaina Adnan (Z)

Zvulun Medical Center, Clalit Medical Services, Kiryat Bialik 2706716, Israel.
Azrieli Faculty of Medicine, Bar Ilan University, Sefad 1311502, Israel.

Dania Hirsch (D)

Institute of Endocrinology, Rabin Medical Center - Beilinson Hospital, Petach Tikva 4941492, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Hadar Duskin-Bitan (H)

Institute of Endocrinology, Rabin Medical Center - Beilinson Hospital, Petach Tikva 4941492, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Amit Akirov (A)

Institute of Endocrinology, Rabin Medical Center - Beilinson Hospital, Petach Tikva 4941492, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH